6,706 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Bought by Isthmus Partners LLC

Isthmus Partners LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 6,706 shares of the biopharmaceutical company's stock, valued at approximately $321,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HALO. Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter worth $29,000. Smartleaf Asset Management LLC increased its stake in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 197 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in Halozyme Therapeutics in the 4th quarter worth about $69,000. Parkside Financial Bank & Trust raised its holdings in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 322 shares during the period. Finally, Farther Finance Advisors LLC grew its holdings in Halozyme Therapeutics by 173.6% in the third quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company's stock valued at $93,000 after purchasing an additional 1,028 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the sale, the director now owns 33,611 shares in the company, valued at approximately $1,972,629.59. This trade represents a 12.95 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the transaction, the senior vice president now owns 185,453 shares of the company's stock, valued at approximately $10,765,546.65. This represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 31,697 shares of company stock valued at $1,754,451 in the last 90 days. Company insiders own 2.40% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Benchmark reiterated a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Piper Sandler increased their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. Wells Fargo & Company cut their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $62.78.

Halozyme Therapeutics Price Performance

Shares of HALO stock traded up $1.21 during trading hours on Friday, reaching $62.27. The company had a trading volume of 1,042,419 shares, compared to its average volume of 1,312,358. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $65.53. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The company has a market capitalization of $7.67 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 0.42 and a beta of 1.32. The stock has a fifty day moving average of $56.76 and a 200-day moving average of $54.76.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.